Market capitalization | $7.01b |
Enterprise Value | $6.14b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 11.80 |
P/S ratio (TTM) P/S ratio | 13.47 |
P/B ratio (TTM) P/B ratio | 6.28 |
Revenue growth (TTM) Revenue growth | 122.96% |
Revenue (TTM) Revenue | $520.18m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
26 Analysts have issued a Legend Biotech Corp - ADR forecast:
26 Analysts have issued a Legend Biotech Corp - ADR forecast:
Sep '24 |
+/-
%
|
||
Revenue | 520 520 |
305%
305%
|
|
Gross Profit | 305 305 |
-
|
|
EBITDA | -329 -329 |
-
|
EBIT (Operating Income) EBIT | -351 -351 |
21%
21%
|
Net Profit | -348 -348 |
13%
13%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Legend Biotech Corporation develops cell therapy solutions for cancer patients. The company was founded in 2014 and is based in Cayman Islands. The company operates as a subsidiary of Genscript Biotech Corporation.
Head office | Cayman Islands |
CEO | Ying Huang |
Employees | 1,826 |
Founded | 2014 |
Website | www.legendbiotech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.